Home / Intelligence / White Papers / Dawn of a New Era: Evolving Needs, Solutions and Technology in U.S. HEOR
The U.S. health economics and outcomes research (HEOR) field has seen many changes over the last decade, including significant growth driven by payers, regulators and clinicians who are increasingly looking to Real-World Evidence (RWE) as a valuable source for patient-level data. To understand the implications of this growth, the Trinity Life Sciences Evidence Strategy team sought to gain a multi-disciplinary view on where and how HEOR experts see the field evolving and to better understand how HEOR capabilities can be best leveraged across the life sciences industry to improve patient outcomes.
Our goal was to gather HEOR thought leaders across the industry including representatives from pharmaceutical, medical devices/diagnostics and academia to weigh in on these topics. The objective was to gather perspectives on an extensive range of topics including the future of HEOR as a field, its ability to drive decision-making, its central role across the entire lifecycle and evidence generation overall—both in the U.S. and abroad. Our discussions centered around how HEOR and evidence generation will play a role in the evolution of the life sciences industry, from pharmaceuticals and biotechnology to devices and diagnostics. Most importantly, we discussed outcomes overall–including the individual and societal levels, as well as public health. Across the interviews, the discussion focused on the growing importance of Real-World Data (RWD) and specifically on data on social determinants of health (SDOH) and patient-reported outcomes (PROs).
In the paper that follows, we share with you our findings, the methods we used and most importantly, the great perspectives we heard. In addition, we offer (often in the words of the respondents themselves) insights into the current and future field of HEOR and evidence generation overall, articulating why this is an important function for any aspiring life sciences company. Through this initiative, we begin to illuminate how the healthcare industry can best utilize the HEOR specialty to unlock the potential value in a therapy or technology via rigorous analyses and well-articulated value stories.
Complete the form below to access the full whitepaper
The Future of AI for Market Access: An ISPOR US 2023 Recap
This year Trinity team members at ISPOR 2023 attended several symposia and presentations on the use of Artificial Intelligence (AI) to support biopharma evidence generation. Among many industry trends, experts anticipate that AI and machine learning will increasingly be leveraged to identify optimal patient populations and expedite the path toward personalized medicine. Pioneering New Frontiers […]
ISPOR 2023 Trinity Panel: Enabling Patient Access to Digital Therapeutics – The Optimal Approach?
Monica Martin de Bustamante, Sr. Partner of Trinity’s Evidence, Value, Access, and Pricing (EVAP) team, moderated an exciting conversation at ISPOR 2023 Global in Boston earlier this month. Monica spoke with Lisa Marsch, Ph.D., Benjamin Parcher, PharmD, MS, and Fulton Velez, MD, MS, MBA, all experts in the field of Digital Therapeutics (DTx), about the […]
Generating Robust Insights to Develop a Compelling Value Story with RWE
Available On Demand
The unprecedented availability of rich RWE data sources gives HEOR, Value and Access and Medical leaders the opportunity to be more intentional than ever before. High-quality, compelling evidence is now a necessity, not just for high-value therapies playing in the rare disease space—but also more broadly, to show reduced unmet needs, health care resource utilization […]